资讯
MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection ...
This demographic shift is placing immense strain on health and social care systems worldwide, and calls for bold, innovative ...
The company has looked internally for its new leader, as Doustdar is currently serving as its head of international ...
Melanoma is the fifth most common cancer in the UK, accounting for around 4% of all new cancer cases. While immunotherapy is ...
At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...
Diagnostics provide the insight, but only a connected pathway turns that insight into real-world impact. That means ensuring ...
The White House has confirmed that the trade deal signed with the EU – which includes an overarching tariff rate of 15% on ...
In a statement, the Cambridge, Massachusetts-based company said that shipments of Elevidys (delandistrogene moxeparvovec) will restart while it continues dialogue with the FDA "on next steps in the ...
In 2023 the FDA published guidance on rare diseases. The guidance recognises that many rare diseases are serious conditions ...
Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...
Bayer's rivalry with Boehringer Ingelheim in the development of medicines for HER2-mutated non-small cell lung cancer (NSCLC) ...
AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibody-drug conjugate (ADC ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果